Does the media prefer BDX or PODD?

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than Insulet. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 14 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.42 beat Insulet's score of 1.09 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 17 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, PODD or DXCM?

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.69 $247.10M $4.30 33.59 DexCom $4.66B 5.74 $836.30M $2.34 29.63

Is PODD or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% DexCom 19.31% 33.33% 13.19%

Does the media refer more to PODD or DXCM?

In the previous week, DexCom had 14 more articles in the media than Insulet. MarketBeat recorded 28 mentions for DexCom and 14 mentions for Insulet. Insulet's average media sentiment score of 1.09 beat DexCom's score of 1.03 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 17 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PODD or RMD?

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.69 $247.10M $4.30 33.59 ResMed $5.15B 5.39 $1.40B $10.37 18.42

Is PODD or RMD more profitable?

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% ResMed 27.44% 25.35% 18.69%

Does the media refer more to PODD or RMD?

In the previous week, Insulet had 2 more articles in the media than ResMed. MarketBeat recorded 14 mentions for Insulet and 12 mentions for ResMed. Insulet's average media sentiment score of 1.09 beat ResMed's score of 0.82 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, PODD or STE?

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.69 $247.10M $4.30 33.59 STERIS $5.94B 3.32 $782.30M $7.93 25.46

Is PODD or STE more profitable?

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 10.44% 26.87% 12.01% STERIS 13.18% 14.15% 9.52%

Does the media refer more to PODD or STE?

In the previous week, Insulet had 7 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Insulet and 7 mentions for STERIS. Insulet's average media sentiment score of 1.09 beat STERIS's score of 1.00 indicating that Insulet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, GMED or PODD?

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $3.10B 3.52 $537.87M $4.30 18.70 Insulet $2.71B 3.69 $247.10M $4.30 33.59

Is GMED or PODD more profitable?

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% Insulet 10.44% 26.87% 12.01%

Does the media favor GMED or PODD?

In the previous week, Globus Medical and Globus Medical both had 14 articles in the media. Insulet's average media sentiment score of 1.09 beat Globus Medical's score of 0.81 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Insulet (PODD) Competitors

$144.64 +5.67 (+4.08%)

As of 01:34 PM Eastern

Compare

PODD vs. BDX, DXCM, RMD, STE, and GMED

Should you buy Insulet stock or one of its competitors? MarketBeat compares Insulet with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insulet include Becton, Dickinson and Company (BDX), DexCom (DXCM), ResMed (RMD), STERIS (STE), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.

How does Insulet compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Becton, Dickinson and Company has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than Insulet. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 14 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.42 beat Insulet's score of 1.09 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	17 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet has a net margin of 10.44% compared to Becton, Dickinson and Company's net margin of 5.33%. Insulet's return on equity of 26.87% beat Becton, Dickinson and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
Insulet	10.44%	26.87%	12.01%

Becton, Dickinson and Company currently has a consensus target price of $181.00, suggesting a potential upside of 24.84%. Insulet has a consensus target price of $238.67, suggesting a potential upside of 65.23%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75

Becton, Dickinson and Company has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	1.83	$1.68B	$3.95	36.71
Insulet	$2.71B	3.69	$247.10M	$4.30	33.59

Summary

Insulet beats Becton, Dickinson and Company on 9 of the 16 factors compared between the two stocks.

How does Insulet compare to DexCom?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
DexCom	19.31%	33.33%	13.19%

97.8% of DexCom shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.69	$247.10M	$4.30	33.59
DexCom	$4.66B	5.74	$836.30M	$2.34	29.63

Insulet has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

In the previous week, DexCom had 14 more articles in the media than Insulet. MarketBeat recorded 28 mentions for DexCom and 14 mentions for Insulet. Insulet's average media sentiment score of 1.09 beat DexCom's score of 1.03 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	17 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet currently has a consensus target price of $238.67, suggesting a potential upside of 65.23%. DexCom has a consensus target price of $84.88, suggesting a potential upside of 22.43%. Given Insulet's higher probable upside, research analysts clearly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

DexCom beats Insulet on 11 of the 17 factors compared between the two stocks.

How does Insulet compare to ResMed?

Insulet (NASDAQ:PODD) and ResMed (NYSE:RMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.69	$247.10M	$4.30	33.59
ResMed	$5.15B	5.39	$1.40B	$10.37	18.42

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
ResMed	27.44%	25.35%	18.69%

55.0% of ResMed shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.7% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Insulet presently has a consensus price target of $238.67, suggesting a potential upside of 65.23%. ResMed has a consensus price target of $270.82, suggesting a potential upside of 41.75%. Given Insulet's stronger consensus rating and higher probable upside, research analysts clearly believe Insulet is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Insulet has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, ResMed has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

In the previous week, Insulet had 2 more articles in the media than ResMed. MarketBeat recorded 14 mentions for Insulet and 12 mentions for ResMed. Insulet's average media sentiment score of 1.09 beat ResMed's score of 0.82 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ResMed beats Insulet on 9 of the 17 factors compared between the two stocks.

How does Insulet compare to STERIS?

Insulet (NASDAQ:PODD) and STERIS (NYSE:STE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.69	$247.10M	$4.30	33.59
STERIS	$5.94B	3.32	$782.30M	$7.93	25.46

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
STERIS	13.18%	14.15%	9.52%

94.7% of STERIS shares are held by institutional investors. 0.4% of Insulet shares are held by company insiders. Comparatively, 1.1% of STERIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Insulet currently has a consensus price target of $238.67, indicating a potential upside of 65.23%. STERIS has a consensus price target of $278.00, indicating a potential upside of 37.69%. Given Insulet's higher possible upside, research analysts plainly believe Insulet is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Insulet has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, STERIS has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

In the previous week, Insulet had 7 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Insulet and 7 mentions for STERIS. Insulet's average media sentiment score of 1.09 beat STERIS's score of 1.00 indicating that Insulet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insulet beats STERIS on 9 of the 15 factors compared between the two stocks.

How does Insulet compare to Globus Medical?

Globus Medical (NYSE:GMED) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Globus Medical has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$3.10B	3.52	$537.87M	$4.30	18.70
Insulet	$2.71B	3.69	$247.10M	$4.30	33.59

95.2% of Globus Medical shares are held by institutional investors. 18.4% of Globus Medical shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Globus Medical and Globus Medical both had 14 articles in the media. Insulet's average media sentiment score of 1.09 beat Globus Medical's score of 0.81 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical presently has a consensus price target of $105.00, suggesting a potential upside of 30.60%. Insulet has a consensus price target of $238.67, suggesting a potential upside of 65.23%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87
Insulet	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.75

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
Insulet	10.44%	26.87%	12.01%

Summary

Insulet beats Globus Medical on 8 of the 15 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PODD vs. The Competition

Export

Metric	Insulet	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.00B	$8.13B	$6.50B	$12.20B
Dividend Yield	N/A	2.55%	2.68%	5.81%
P/E Ratio	33.56	15.26	24.67	24.11
Price / Sales	3.69	5.56	532.48	112.06
Price / Cash	23.05	17.32	27.92	37.84
Price / Book	6.71	3.25	10.89	6.57
Net Income	$247.10M	$226.25M	$3.56B	$336.88M
7 Day Performance	-2.20%	-2.97%	2.19%	0.21%
1 Month Performance	-6.73%	-3.02%	0.94%	1.23%
1 Year Performance	-53.05%	2.48%	33.91%	32.52%

Insulet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PODD Insulet	4.6554 of 5 stars	$144.44 +3.9%	$238.67 +65.2%	-54.2%	$10.00B	$2.71B	33.56	5,400	Positive News Analyst Forecast Gap Up
BDX Becton, Dickinson and Company	4.9387 of 5 stars	$145.61 -0.4%	$182.73 +25.5%	-16.7%	$40.30B	$21.84B	36.86	72,000	Positive News
DXCM DexCom	4.7228 of 5 stars	$74.22 -1.5%	$84.83 +14.3%	-13.7%	$29.08B	$4.66B	31.72	11,000	Positive News Analyst Forecast
RMD ResMed	4.9443 of 5 stars	$193.05 -0.9%	$279.82 +44.9%	-25.7%	$28.25B	$5.15B	18.62	10,600	Analyst Forecast
STE STERIS	4.9095 of 5 stars	$205.80 -0.9%	$278.00 +35.1%	-15.0%	$20.23B	$5.94B	25.95	17,937	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PODD) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insulet (PODD) Competitors

PODD vs. BDX, DXCM, RMD, STE, and GMED

How does Insulet compare to Becton, Dickinson and Company?

Summary

How does Insulet compare to DexCom?

Summary

How does Insulet compare to ResMed?

Summary

How does Insulet compare to STERIS?

Summary

How does Insulet compare to Globus Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insulet (PODD) Competitors

PODD vs. BDX, DXCM, RMD, STE, and GMED

How does Insulet compare to Becton, Dickinson and Company?

Which has more volatility and risk, BDX or PODD?

Do institutionals & insiders believe in BDX or PODD?

Does the media prefer BDX or PODD?

Is BDX or PODD more profitable?

Do analysts rate BDX or PODD?

Which has stronger earnings and valuation, BDX or PODD?

Summary

How does Insulet compare to DexCom?

Is PODD or DXCM more profitable?

Do institutionals and insiders hold more shares of PODD or DXCM?

Which has stronger valuation & earnings, PODD or DXCM?

Which has more risk and volatility, PODD or DXCM?

Does the media refer more to PODD or DXCM?

Do analysts recommend PODD or DXCM?

Summary

How does Insulet compare to ResMed?

Which has stronger earnings & valuation, PODD or RMD?

Is PODD or RMD more profitable?

Do institutionals & insiders hold more shares of PODD or RMD?

Do analysts rate PODD or RMD?

Which has more risk and volatility, PODD or RMD?

Does the media refer more to PODD or RMD?

Summary

How does Insulet compare to STERIS?

Which has better earnings and valuation, PODD or STE?

Is PODD or STE more profitable?

Do institutionals & insiders have more ownership in PODD or STE?

Do analysts rate PODD or STE?

Which has more volatility and risk, PODD or STE?

Does the media refer more to PODD or STE?

Summary

How does Insulet compare to Globus Medical?

Which has more volatility & risk, GMED or PODD?

Which has better valuation & earnings, GMED or PODD?

Do insiders and institutionals have more ownership in GMED or PODD?

Does the media favor GMED or PODD?

Do analysts rate GMED or PODD?

Is GMED or PODD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools